Psychedelic medicine sits at the crossroads of mental health research and wider pharmaceutical development, and AbbVie’s US$1b commitment has pushed this theme firmly onto many watchlists. With global PMIs sending mixed signals on growth, inflation and policy paths, some investors are looking for targeted exposure to areas where clinical pipelines, rather than broad economic momentum, can be a key driver of value. This Psychedelic Stocks In The Space AbbVie Bet A Billion Dollars On screener narrows that universe, and the rest of this article walks through 3 of the most interesting stocks surfaced by that process.

Optimi Health (CNSX:OPTI)

Overview: Optimi Health is a Canadian pharmaceutical and nutraceutical manufacturer that produces GMP grade MDMA, psilocybin, other psychedelics and functional mushroom products for clinics, clinical trials, pharmacies and wellness customers. It sells both finished drug products and supplements through partners and online channels.

Operations: Optimi Health currently generates around CA$0.2m in revenue from the farming, processing and distribution of agrifoods.

Market Cap: CA$33.19m

Optimi Health provides exposure to the supply chain behind psychedelic medicine, rather than the headline clinical trials. The company is still at a very early stage, with less than US$1m in revenue, ongoing losses and a high P/B multiple. Shareholders have been diluted, while the share price has been highly volatile and has lagged the broader Canadian market. At the same time, Optimi has a fully licensed GMP facility in Canada, growing interest from international programs in Australia, Europe, the U.S. and the UK, and a pipeline that spans psilocybin, MDMA and ibogaine. An important consideration for investors is whether this vertically integrated footprint can eventually justify the current valuation and funding risks.

Optimi Health’s fully licensed GMP facility and tiny revenue base hint at something investors may be underappreciating. See how the current valuation, dilution and balance sheet pressure line up in the Optimi Health financial health report.

COMPASS Pathways (CMPS)

Overview: COMPASS Pathways is a UK-based biotechnology company focused on mental health, developing its COMP360 psilocybin therapy for treatment resistant depression in Phase III trials and for post traumatic stress disorder and anorexia nervosa in Phase II trials across the United Kingdom and the United States.

Market Cap: US$1.70b

COMPASS Pathways is attracting attention because it sits at the front of late stage psychedelic medicine, with COMP360 in Phase III for treatment resistant depression and positive engagement with the FDA on a rolling approval process that could be pivotal for future revenue. The company is already preparing for commercialization by building relationships with interventional psychiatry centers that currently administer Spravato. This could help translate any approval into prescription volume more quickly. At the same time, investors need to weigh the usual biotech risks, including reliance on successful trial outcomes, regulatory decisions and the company’s use of higher risk external funding and shareholder dilution. The combination of advanced clinical data, regulatory momentum and financial trade offs is what makes COMPASS worth a closer look.

COMPASS Pathways is moving toward late stage commercialization. However, the real story is how that clinical progress compares with its funding choices and dilution risks, which show up clearly in the COMPASS Pathways financial health report.

Incannex Healthcare (IXHL)

Overview: Incannex Healthcare is a Sydney-based clinical stage biopharmaceutical company developing psychedelic and cannabinoid based therapies, including IHL-42X for obstructive sleep apnea and PSX-001, an oral synthetic psilocybin, for generalized anxiety disorder, alongside an anti inflammatory combination drug for a range of chronic respiratory and autoimmune conditions.

Market Cap: US$39.60m

Incannex Healthcare brings together two large unmet markets, sleep apnea and anxiety, with psychedelic and cannabinoid drug candidates that already have Phase II data and FDA Fast Track status for IHL-42X. The company is still very early, with less than US$1m in revenue, ongoing losses, a return on equity that reflects sustained unprofitability and recent shareholder dilution, so financing and execution risk remain front and center. What keeps Incannex on watchlists is the combination of an experienced management team, active late stage trial preparation and a P/B ratio that is below both peers and the wider US pharmaceuticals sector. The key consideration for investors is how that mix of clinical momentum and balance sheet pressure compares when examined in more detail.

Incannex Healthcare’s mix of psychedelic and cannabinoid trials with FDA Fast Track status hints at a story many investors may be glossing over. See how the balance sheet, valuation and clinical setup intersect in the Incannex Healthcare financial health report.

The three psychedelic stocks covered here are only a starting point, as the full Psychedelic Stocks In The Space AbbVie Bet A Billion Dollars On screener surfaces 24 more companies where psychedelic pipelines, mental health franchises and broader life sciences exposure create equally compelling narratives. Use Simply Wall St to identify and analyze the specific catalysts, regulatory milestones, balance sheet strength and valuation setups that are most relevant so you can focus on the opportunities that best fit your investment approach in this emerging theme.

Take Control of Your Investment Journey

If Optimi Health or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh stock ideas can shift from quiet accumulation to full breakout quickly, and the best entry points often pass once momentum is caught. Scan these under the radar setups and consider your options promptly.

1. Spot companies quietly building momentum by running the 18 high quality undiscovered gems and see which stocks are still flying below most investors’ screens while it matters.
2. Target resilient compounders that may continue moving when others stall by checking the curated 69 resilient stocks with low risk scores before the crowd focuses on their steadier profiles.
3. Explore the next leg of the AI build out by scanning 49 AI infrastructure stocks and find the enablers behind data centers, chips and power upgrades before prices potentially move away from current levels.

Simply Wall St analyst Bailey Pemberton and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.